The present invention relates to the field of biochemistry, specifically to the bioproduction of glycolate. Host cells, especially cyanobacteria of the genus Synechocystis, are modified in several ways to increase extracellular glycolate, including: mutant Rubisco enzymes, overexpression of phosphoribulokinase (PRK) or phosphoglycolate phosphatase (PGP), a permease to export glycolate, like GIcA, or by reduction of the capacity to metabolize glycolate due to reduced or eliminated glycolate dehydrogenase, glycolate oxidase activity and/or lactate dehydrogenase.

Disclosed are engineered nucleases that bind and cleave a recognition sequence within a hydroxyacid oxidase 1 (HAO1) gene. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells. Further, the invention encompasses pharmaceutical compositions comprising engineered nuclease proteins or nucleic acids encoding engineered nucleases of the invention, and the use of such compositions for treatment of primary hyperoxaluria type I.

The present invention provides methods and compositions for treating a pediatric subject having primary hyperoxaluria and methods for preventing at least one symptom in a pediatric subject having primary hyperoxaluria. The methods include administering to the subject a therapeutically effective amount or a prophylactically effective amount of an RNAi agent, e.g., double-stranded RNAi agent, targeting HAO1.

A sensor implanted in tissues and including a sensing layer is fabricated by mixing the signal transduction enzyme with non-reactive components including buffer salts and fillers, and spin coating the enzyme onto a substrate. The signal transduction enzyme is crosslinked by introducing the coated substrate in a vacuum chamber. In the chamber, a crosslinker evaporates and is deposited onto the enzyme, therefore crosslinking the enzyme.

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.

A sensor implanted in tissues and including a sensing layer is fabricated by mixing the signal transduction enzyme with non-reactive components including buffer salts and fillers, and spin coating the enzyme onto a substrate. The signal transduction enzyme is crosslinked by introducing the coated substrate in a vacuum chamber. In the chamber, a crosslinker evaporates and is deposited onto the enzyme, therefore crosslinking the enzyme.

The invention relates to a device and method for detecting a specific analyte in a liquid sample. The device that can be used in the method contains at least one fluid line, at least one receiving region for receiving a liquid sample, at least one enzymes region containing at least one determined enzyme and/or at least one acidification region containing at least one acid. The device also contains at least one reaction region used to form gas bubbles. The fluid line transports the liquid sample from the receiving region via the enzyme region and/or the acidification region to the reaction region by means of capillary forces and/or at least one micropump allowing fast, simple and cost-effective detection of a specific analyte in a liquid sample, the detection being carried out with a high level of sensitivity, specificity and precision. The invention further relates to uses of the device.

The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having primary hyperoxaluria, e.g., PH1.